Overview
MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
Featured Links
Receive E-mail Alerts | Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now! |
|  | |
 |
| Date | Title | | | 02/02/12 | MannKind Receives Commitment from The Mann Group to Acquire 31,250,000 Shares of Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 2, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that it has
entered into a purchase agreement with The Mann Group LLC, an entity
controlled by MannKind’s chief executive officer and principal
stockholder, Alfred E. Mann, for the sale of shares of its common stock
to The Mann Group. The Mann Group has committed to purchase 31,250,000
restricted shares of MannKind’s common stock, the same number of ... |
|  | | 02/02/12 | MannKind Announces Pricing of Public Offering of Units Consisting of Common Stock and Warrants to Purchase Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 2, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced the pricing
of an underwritten public offering of 31,250,000 units, with each unit
consisting of one share of its common stock and a warrant to purchase
0.6 of a share of its common stock. The shares of common stock and the
warrants are being offered at a combined price to the public of $2.40
per unit. The gross proceeds to MannKind from this offerin... |
|  | | 01/31/12 | MannKind Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock| VALENCIA, Calif.--(BUSINESS WIRE)--Jan. 31, 2012--
MannKind Corporation (Nasdaq: MNKD) today announced that it
intends to offer and sell, subject to market and other conditions, $50
million worth of units in an underwritten public offering, with each
unit consisting of one share of MannKind’s common stock and a warrant to
purchase 0.6 of a share of MannKind’s common stock. MannKind also
intends to grant to the underwriters of the offering an option t... |
|  | | 01/05/12 | MannKind to Present at 30th Annual J.P. Morgan Healthcare Conference| VALENCIA, Calif.--(BUSINESS WIRE)--Jan. 5, 2012--
MannKind Corporation (Nasdaq: MNKD), focused on discovering,
developing and commercializing treatments for diabetes and cancer,
announced today that it will present at the 30th Annual J.P. Morgan
Healthcare Conference on Thursday, January 12, 2012 at 8:00 am (PT) at
the Westin St. Francis Hotel in San Francisco, California.
Interested parties can access a link to the live webcast of the
... |
|  |
|
 |
|